The State of Non-Invasive Blood Glucose Monitoring in Wearable Technology

Major consumer electronics companies are currently unable to offer FDA-cleared, non-invasive blood glucose monitoring in smartwatches. While firms like Apple, Samsung, and Oura are researching methods to track metabolic health, current industry standards rely on traditional glucometers or continuous glucose monitors (CGMs) that utilize interstitial fluid sensors. To date, no wearable device on the market can replace a medical-grade blood sugar test for clinical decision-making.

Why non-invasive glucose tracking remains a technical hurdle

Tracking blood glucose without piercing the skin requires measuring glucose levels in sweat, tears, or through skin tissue using optical sensors. According to the U.S. Food and Drug Administration (FDA), no smartwatch or ring currently has the authorization to measure blood glucose levels. The primary engineering challenge involves the “signal-to-noise” ratio; glucose concentrations in interstitial fluid or sweat are significantly lower than in blood, and environmental factors like skin temperature, humidity, and movement create interference that optical sensors struggle to filter out accurately.

What is the current status of major tech players?

Companies are approaching metabolic health through different hardware strategies, though none offer direct glucose readings:

• Apple: The company has spent over a decade exploring non-invasive optical absorption spectroscopy, according to Bloomberg. Reports indicate that while the technology has moved from a lab-sized prototype to a more portable device, it is not yet ready for mass-market integration.
• Samsung: The Galaxy Ring and Galaxy Watch focus on “Metabolic Health” metrics, but these are based on lifestyle tracking and heart rate variability rather than direct blood chemistry. Samsung officials have stated they are investing in non-invasive sensor technology but have not provided a timeline for glucose-specific features.
• Oura: The Oura Ring utilizes skin temperature and heart rate to provide insights into recovery and readiness. Like its competitors, Oura does not claim to track glucose, though it integrates with third-party apps like Veri to overlay metabolic data from CGMs.
• Garmin: Garmin focuses on athletic performance and integrates with third-party CGM data via the Connect IQ platform. They have not announced plans to build proprietary glucose-sensing hardware.

How do current wearables compare to medical devices?

There is a distinct functional gap between consumer wearables and medical-grade hardware. A Continuous Glucose Monitor (CGM), such as those produced by Dexcom or Abbott, uses a small filament inserted under the skin to provide real-time data. These devices are classified as Class II medical devices by the FDA. In contrast, current smartwatches and rings are classified as wellness devices. They track proxy metrics—such as activity levels and sleep patterns—which can inform a user about their general health but cannot be used to manage insulin dosing or diagnose diabetes.

What should consumers expect next?

The industry is shifting toward “metabolic flexibility” tracking rather than direct glucose measurement. By using heart rate variability (HRV) and movement data, companies are attempting to estimate how a user’s body responds to stress and activity. According to the American Diabetes Association, users with diabetes should continue to rely on clinically validated glucose meters and CGMs for daily management, as consumer-grade optical sensors currently lack the precision required for clinical safety. Future breakthroughs will likely involve miniaturized spectrometer sensors, but these remain in the research and development phase.

Key Takeaways

• No FDA Approval: No consumer smartwatch or ring is currently authorized to monitor blood glucose.
• Medical vs. Wellness: Wearables provide wellness trends, whereas CGMs provide clinical-grade blood chemistry data.
• Technological Barriers: Measuring blood glucose through the skin involves significant signal interference issues that remain unsolved for mass-market devices.
• Integration over Replacement: Most manufacturers are currently focusing on integrating data from existing medical CGMs into their own health dashboards.